Teplizumab in Pediatric Stage 2 Type 1 Diabetes (PETITE-T1D)

Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants <8 Years of Age With at Least Two Autoantibodies and Dysglycemia)

The purpose of this study is to assess the safety and PK of teplizumab in participants with Stage 2 type 1 diabetes who are <8 years of age.

This is a single-arm, non-randomized, open-label, multicenter study in the U.S. to assess the safety and pharmacokinetics of teplizumab in pediatric participants with Stage 2 type 1 diabetes (T1D) (two T1D-related autoantibodies and dysglycemia) who are 0 to <8 years of age. Anti-drug antibodies/neutralizing antibodies (ADA/NAb) will also be assessed and serologic response to vaccines and exploratory T1D clinical features will be explored. Approximately 20 participants will be enrolled The regimen consists an intravenous infusion of teplizumab once daily for 14 consecutive days. The study duration for each individual may last up to approximately 26 months The safety, tolerability, PK, ADA, and T1D clinical feature data will be summarized using descriptive statistics.

Inclusion Criteria: Participant is a male or female 0 to < 8 years of age, inclusive, at Day 1 Participant has Stage 2 T1D (two T1D-related autoantibodies and dysglycemia) Exclusion Criteria: Participant has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease Has an active infection and/or fever Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.